Back to Search

Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects <=75 Years With Previously Untreated Non-GCB DLBCL


  • Protocol Number: 202102066
  • Principal Investigator: Kahl, Brad
  • Cancer Types: Lymphoma

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions